DCGI approves Hetero’s Tocilizumab for emergency use against Covid-19
The Drugs Controller General of India has approved emergency use of drug firm Hetero’s Tocilizumab for treatment of hospitalised adults suffering from Covid-19. Hetero in a statement said that medical practitioners would be able to use the drug for treating Covid-19 in adults who receive systemic corticosteroids, and even those who require supplemental oxygen, non-invasive or […]
The Drugs Controller General of India has approved emergency use of drug firm Hetero’s Tocilizumab for treatment of hospitalised adults suffering from Covid-19.
Hetero in a statement said that medical practitioners would be able to use the drug for treating Covid-19 in adults who receive systemic corticosteroids, and even those who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
Hetero Group Chairman B Partha Saradhi Reddy said this approval is extremely crucial for supply security in India considering a global shortage of Tocilizumab.
The drug firm’s Tocilizumab would be available in the market by September end.
Hetero’s associate company Hetero Healthcare will market its biosimilar version of Tocilizumab under the brand name Tocira, PTI reported.
